Lineage Cell Therapeutics (LCTX) EBT Margin (2010 - 2026)

Lineage Cell Therapeutics has reported EBT Margin for 17 years, with the latest figure at 416.7% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin fell 1543.0% year-over-year to 416.7%; the trailing twelve-month figure through Mar 2026 stood at 93.15% (up 9572.0% YoY), and the FY2025 full-year result was 471.61%, down 27599.0% from the prior year.
• EBT Margin for Q1 2026 stood at 416.7%, down from 244.66% in the prior quarter.
• The five-year high for EBT Margin was 244.66% in Q4 2025, with the low at 698.95% in Q2 2025.
• Historically, EBT Margin has averaged 261.55% across 5 years, with a median of 225.77% in 2023.
• Annual changes were most pronounced in 2022 — EBT Margin soared 82077 bps — and 2023, when it slumped 38852 bps.
• Lineage Cell Therapeutics' EBT Margin stood at 332.22% in 2022, then soared by 32 bps to 225.77% in 2023, then surged by 50 bps to 113.32% in 2024, then soared by 316 bps to 244.66% in 2025, then sank by 270 bps to 416.7% in 2026.
• The last three EBT Margin figures came in at 416.7% (Q1 2026), 244.66% (Q4 2025), and 92.91% (Q3 2025), per Business Quant data.